2018 American Transplant Congress » Poster Session D: Liver: Viral Hepatitis

6:00pm-7:00pm

A Comparison of the Discard Rate in Hepatitis C Deceased Liver Donors between Two Eras, 2008-2013 and 2014-2017. A Single Organ Procurement Organization Experience

M. Nazzal,¹ G. Marklin,² O. Okoye,¹ Y. Kim,¹ R. Ouseph.¹

6:00pm-7:00pm

Benefit of Anti-Hepatitis B Immunoglobulin(HBIG) Monotherapy Compared to HBIG Combined with Entecavir in Long Term Renal Function

J. Lee,¹ D. Kim,¹ J. Lee,² S. Kim,³ H. Lee,⁴ S. Song,⁵ J. Lee,¹ M. Ju,¹ G. Choi,¹ D. Joo,¹ J. Choi,¹ S. Kim,¹ Y. Jung.¹

6:00pm-7:00pm

Effect of Direct-Acting Hepatitis C Treatment Regimens on Calcineurin Inhibitors in Liver and Kidney Transplant Patients

M. Laub, J. Byrns, M. Harris, C. Berg, S. Sanoff.

6:00pm-7:00pm

Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus

H. Joharji, A. Al-Jedai, D. Alkortas, A. Ajlan, E. Devol, M. Ahmed, F. Aba Al-Khail, H. El-Siesy, M. Al-Sebayel, H. Al-Ashgar, M. Al-Quaiz, W. Alhomodi, A. Aloubal, A. Almohishir.

6:00pm-7:00pm

Hepatitis C Recurrence after Liver Transplant: A Comparison of Antibody Induction versus No Antibody Induction

S. Patel, J. Jin, E. Benedetti, P. West-Thielke.

6:00pm-7:00pm

Outcomes of Antiviral Treatment (AVT) in Hepatitis C Virus (HCV) Liver Transplant (LT) Patients off Immunosuppression (IS) in Direct Acting Antivirals (DAA) Era

E. Agudelo,^1,2 I. Campos-Varela,³ N. Terrault.^1,2

6:00pm-7:00pm

Renal and Bone Safety in Post Liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis

E. Gane,¹ B. George,¹ S. Munn,¹ H. Wang,² V. Suri,² A. Gaggar.²

6:00pm-7:00pm

Treatment and Outcomes of Orthotopic Liver Transplant Patients Secondary to Hepatitis C Virus: A Single Center Experience

T. Chen,¹ M. Moaddab,¹ B. Pierce,¹ R. Ghobrial.²